Drug Patents owned by Secura
1. List of Copiktra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(6 years from now) | |
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(5 years from now) | |
| US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(8 years from now) | |
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 2022-09-24
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
COPIKTRA family patents
34
United States
10
European Union
9
New Zealand
8
Singapore
7
Japan
7
China
6
Korea, Republic of
6
Ukraine
6
Russia
6
Mexico
5
Australia
5
Israel
4
Canada
4
Malaysia
4
Philippines
4
Brazil
4
South Africa
3
Denmark
3
Spain
3
Hong Kong
3
Taiwan
2
Peru
2
Argentina
1
India
1
Croatia
1
Netherlands
1
Chile
1
Cyprus
1
Portugal
1
Poland
1
Slovenia
1
San Marino
1
Hungary
1
Lithuania
2. List of Farydak drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 23, 2022 |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
Market Authorisation Date: 23 February, 2015
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE;ORAL
FARYDAK family patents
10
United States
5
Korea, Republic of
5
Japan
4
China
3
European Union
2
Australia
2
Canada
2
Mexico
2
Brazil
2
Taiwan
1
Ecuador
1
EA
1
Israel
1
Denmark
1
Honduras
1
Spain
1
Uruguay
1
Tunisia
1
Peru
1
Malaysia
1
Costa Rica
1
Nicaragua
1
Chile
1
ME
1
Cyprus
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Russia
1
Morocco
1
Norway
1
Slovenia
1
Georgia
1
Argentina
1
South Africa
1
San Marino
1
Guatemala
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic